Abstract:BACKGROUND:Despite recent reforms, distorting funding mechanisms and over-prescribing still maintain severe financial barriers to medicines access in China. Complicated and interrelated problems in the pharmaceutical sector require a common framework to be resolved as fragmented solutions do not work. We present a preliminary assessment of the impact of the national healthcare reforms on access to medicines, and propose policy recommendations for promoting universal access to medicines in China.METHODS:Drawing on multiple sources of information, including a review of published literatures and official national data, field investigations in six provinces and interviews with key opinion leaders, this paper presents a preliminary assessment of the impact of the national healthcare reforms on access to medicines, and proposes policy recommendations for promoting universal access to medicines in China.RESULTS:Public expenditure on medicines has been strictly controlled since the national healthcare reforms of 2009. Yet total pharmaceutical expenditure (TPE) and total health expenditure growth rates continuously outpaced the growth of gross domestic product (GDP). With 2.4% of GDP, TPE now exceeds that of most high income countries. The distorted provider and consumer incentives in the Chinese health system have not fundamentally changed. Price-setting and reimbursement mechanisms do not promote cost-effective use of medicines. Inappropriate price controls and perverse financial incentives are the un-resolved root causes of preference of originator brands for some major diseases and shortages of low-cost and low-consumption medicines. In addition, access to expensive life-saving medicines is yet systematically addressed.CONCLUSIONS:The complicated and interdependent problems interact in a way that leads to significant system problems in China, which create dual challenges that both the developing country and the developed countries are facing. To further promote access to medicines, China should speed up the re-assessment of the quality and efficacy of domestically produced generic medicines; coordinate various reforms of price determination, insurance payments, and procurement policies; address medicine shortages through comprehensive policies and legislation; establish specific mechanisms to achieve sustainable equitable access to expensive essential medicines with health technology assessment as a tool to ensure that policy and priority setting are created in a coherent and evidence-based way.

Problem and countermeasure in technology transfer of medicine in China

Analysis on the Causes and Countermeasures of the Dilemma in Medical Patents Transfer

Health Technology Assessment and Its Use in Drug Policies in China

Practice and reflection on international technology transfer in clinical hospitals: Take Peking University Third Hospital as an example

A Review of Promoting Access to Medicines in China - Problems and Recommendations.

Problems and Reform Strategies of Medicines Distribution System in China

The Evolution,Problems and Implications of Chinese Technology Transfer Policy since Reform and Opening-up

International Experiences of Response to Medicines Shortage and the Implications to China

A Preliminary Study on Clinical Research Transfer

Revolutionizing pharmaceutical innovation: Unveiling the impact of endogenous knowledge spillover in China

Translational Medicine Should Translate Medical Science and Technology into Health Care for Everyone in China

International Trade Barriers and Countermeasures of Chinese Medicinal Materials Based on Big Data

Problems and Countermeasures on Transformation of Agricultural Science and Technology Achievements

Technology Transfer And R&D In Multinational Corporations (Mncs) - Policy Implication For China

A Tentative Study on the Consummation of the Legal System of Transferring Patent Rights to Foreigners

[Application status and safety countermeasures of traditional Chinese medicine injections]

Problems and Countermeasures for Innovative Pharmaceutical Talents Training

Analysis on the Promotion of Patent Conversion Strategy of Traditional Chinese Medicine

[A Strategy of Constructing the Technological System for Quality Control of Chinese Medicine Based on Process Control and Management].

[Four critical engineering and technical problems in manufacturing measurement of traditional Chinese medicine].

Market access of Chinese patent medicine products to healthcare security system in China: implications for international integration of traditional medicine into health systems